ClinicalTrials.gg
RecruitingNCT07009171Updated Jun 24, 2026

Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

A Phase 2 interventional study of KDS2010 and KDS2010 in Overweight, Obesity and Obese Patients, sponsored by NeuroBiogen Co., Ltd. Recruiting at 3 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NeuroBiogen Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 137 studies in Obesity with a site in Korea, Republic of — 35 open to participants now, 46 under way, 27 of them phase 3. Obesity · Korea, Republic of.

Planned enrollment
80th of 117
75 · median 120
Started
2025
with 10 others
Phase 2
7 of 137
1 open now
Primary completion
2027-01
later than 15 of 45 live
Registered
107th of 137
by date

Among the 137 studies in Obesity with a site in Korea, Republic of, this one is the 80th largest by planned enrollment of the 117 interventional ones that give a count, is one of 11 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 15 of the 45 other live ones, and was the 107th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

35 of the 137 studies in Obesity with a site in Korea, Republic of are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Obesity with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, dose-finding, Phase 2a study designed to evaluate the safety and efficacy of KDS2010 in overweight or obese patients. Based on preliminary efficacy observed in the Phase 1 study, this clinical trial is being conducted in Korea.

After a minimum 2-week run-in period, subjects who meet the inclusion and exclusion criteria will be randomized to the treatment group or placebo group at a 2:1 ratio in each stage.

Subjects will receive the investigational product for 12 weeks following randomization. The study will be conducted in three stages.

Approximately 75 subjects will be enrolled, with 6 subjects in the KDS2010 120 mg group and 3 subjects in the placebo group in Stage 1, 22 subjects in the KDS2010 180 mg group and 11 subjects in the placebo group in Stage 2, and 22 subjects in the KDS2010 240 mg group and 11 subjects in the placebo group in Stage 3.

The primary objectives are to assess the efficacy and safety of KDS2010 in overweight or obese patients. Exploratory objectives include evaluating the proportion of subjects achieving a weight reduction of more than 25% from baseline at Week 12 and assessing changes in MAO-B specific activity and adiponectin levels.

Based on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at doses of 120 mg, 180 mg, and 240 mg throughout the study.

Read the detailed description

This Phase 2a, randomized, double-blind, placebo-controlled, dose-finding clinical trial is designed to evaluate the efficacy, safety, and pharmacokinetics of KDS2010, a novel, reversible monoamine oxidase-B (MAO-B) inhibitor, in overweight or obese adult patients. The clinical trial is conducted at selected sites in Korea.

The study consists of three stages and will enroll approximately 75 subjects. In Stage 1, 9 subjects were randomized in a 2:1 ratio (KDS2010 120 mg: placebo) to evaluate initial safety and tolerability. Upon completion of the week 13 visit for the last subject in Stage 1, a Safety Review Committee (SRC) assessed cumulative safety data and determined that the study may proceed to Stage 2.

Stage 2 is currently being prepared for subject recruitment and will proceed with 33 subjects randomized in a 2:1 ratio to receive KDS2010 180 mg or placebo. Upon completion of the Week 13 visit for the last ongoing subject in Stage 2, the SRC will review the safety data collected up to that time to determine whether the study may proceed to Stage 3. Stage 3 will proceed with 33 subjects randomized in a 2:1 ratio to receive KDS2010 240 mg or placebo.

All subjects will undergo a 2-week run-in period prior to randomization to confirm eligibility based on adherence to lifestyle modification (documented reduction of ≥500 kcal/day and ≥150 minutes of physical activity per week for ≥50% of the run-in period).

The treatment period consists of 12 weeks of once-daily oral administration of the investigational product (IP), followed by a 1-week post-treatment safety follow-up (week 13). During treatment, subjects will visit the site at Weeks 4, 8, and 12, with a telephone visit at Week 2. Safety follow-up will be conducted by phone at Week 13.

The primary efficacy endpoint is the percentage change in body weight from baseline to Week 12. Secondary efficacy endpoints include the proportion of subjects achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss and changes in waist circumference, BMI, blood pressure (SBP/DBP), quality of life (IWQOL-Lite-CT), body composition (DEXA), lipid profile, glycemic parameters (HbA1c, fasting glucose, HOMA-IR), and liver steatosis. Exploratory endpoints assess the proportion of subjects with ≥25% weight loss, as well as changes in MAO-B specific activity and adiponectin levels.

Safety will be evaluated through monitoring of adverse events (AEs), laboratory tests, vital signs, ECGs, and psychological assessments, including the Columbia-Suicide Severity Rating Scale (C-SSRS) and Patient Health Questionnaire-9 (PHQ-9). Pharmacokinetic parameters (AUCtau, Cmax,ss, Cmin,ss, Cav,ss, Tmax,ss, t1/2, PTF, etc.) will be measured to assess systemic exposure to KDS2010.

Subjects must be adults aged 19 years or older, have a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, and demonstrate compliance with lifestyle modification during the run-in.

Major exclusion criteria include recent significant weight change (≥5% within 12 weeks), use of anti-obesity drugs or MAO inhibitors, type 1 or 2 diabetes, bariatric surgery, uncontrolled hypertension, hepatic or renal dysfunction, significant psychiatric disorders, or suicidal ideation/attempts.

The total study duration is expected to be approximately 28 months from IRB approval, with individual subject participation lasting up to 17 weeks. This trial aims to evaluate the safety, efficacy, and pharmacokinetics of KDS2010 for future development in the treatment of obesity.

03

Conditions studied

  • Overweight
  • Obesity
  • Obese Patients

Browse trials for

Keywords

  • Obese Patients
  • Overweight
  • KDS2010
  • Obesity
  • MAO-B inhibitor
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 75 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

NeuroBiogen Co., Ltd is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males and females aged 18 years or older (or the legal age of adulthood in the respective country) as of the date of written consent
  • Subjects with ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea) at screening and baseline

    • Hypertension: under treatment or have Systolic Blood Pressure (SBP) ≥130 mmHg or Diastolic Blood Pressure (DBP) ≥80 mmHg
    • Dyslipidemia: under treatment or LDL > 160 mg/dL or TG > 200 mg/dL or HDL \< 40 mg/dL
    • Cardiovascular diseases (e.g., ischemic cardiovascular disease, Class I to III heart failure, Peripheral vascular disease (PVD), Abdominal aortic aneurysm (AAA), etc.)
    • Obstructive sleep apnoea
  • Subjects who have documented a 500 kcal reduction/day in calorie intake and ≥150 minutes of physical activity/week for ≥50% of the time during the run-in period
  • Subjects who have voluntarily provided written consent to participate after being informed about this clinical trial

Exclusion criteria

Exclusion Criteria:

  • Subjects with a weight change of 5% or more within 12 weeks before screening
  • Subjects with less than 80% or more than 120% compliance during the Run-in period
  • Subjects with obesity due to secondary causes (neurological disorders, endocrine disorders, genetic disorders, congenital disorders, etc.)
  • Subjects with following medical history,

    • Type 1 or Type 2 diabetes
    • History of bariatric/metabolic surgery (e.g., adjustable gastric banding, intragastric balloon insertion, sleeve gastrectomy, Roux-en-Y gastric bypass, biliopancreatic diversion, duodenal switch) or planning to undergo such surgery during the study period
    • Heart failure classified as class IV
    • Subjects with a medical history of malignant tumors within 5 years prior to screening (however, subjects with successfully treated basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or other carcinoma in situ, with no recurrence for more than 3 years, may be enrolled at the investigator's discretion)
    • Subjects with a medical history of to MAO inhibitors
    • Subjects with a medical history of cerebrovascular disease (e.g., , stroke) within 12 weeks prior to baseline, or those hospitalized for unstable angina or congestive heart failure
    • Subjects with a history of depressive disorders or psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorder) within 2 years prior to screening
  • Subjects with a history of the following drug administration,

    -- Anti-obesity agents or weight-loss medications (including dietary supplements and herbal medicine) within 12 weeks before screening

    • administered for 2 consecutive weeks or more within 12 weeks before screening (however, topical preparations, including inhalants, are allowed)
    • Treatment for hyperthyroidism or hypothyroidism at the time of screening (subjects on a stable dose and regimen for at least 12 weeks may be enrolled at the investigator's discretion)
    • MAO inhibitors within 2 weeks before baseline
    • Opioid medications (e.g., pethidine, Tramadol, Tapentadol) within 2 weeks before baseline
    • Serotonergic drugs within 2 weeks before baseline,

      • Selective Serotonin Reuptake Inhibitors (SSRI), ② Serotonin-Norepinephrine Reuptake Inhibitors (SNRI),

        • Tricyclic or Tetracyclic antidepressant, ④ Triazolopyridine antidepressant, ⑤ Selective serotonin (5-HT1) agonists (Sumatriptan, etc.), (However, amitriptyline ≤50 mg/day, trazodone ≤100 mg/day, citalopram ≤20 mg/day, sertraline ≤100 mg/day, paroxetine ≤30 mg/day are allowed; long half-life serotonergic drugs (e.g., fluoxetine) require at least a 5-week wash out period before enrollment),
    • Lithium, Bupropion, Lamotrigine, Ritonavir, Cyclobenzaprine, or St. John's wort within 2 weeks before baseline
    • Hypertension crisis-inducing drugs (e.g., oxymetazoline, phentermine, phenylephrine) within 2 weeks before baseline
    • Sympathomimetic agents (e.g., ephedrine, methylphenidate, amphetamine, methamphetamine, lisdexamfetamine) at the time of screening
    • Dextromethorphan at the time of screening
  • Subjects who meet following criteria based on the tests conducted at Screening

    • (HbA1c) ≥6.5%
    • Hepatic impairment ( class C)
    • or ALT > 2.5 X
    • Total >1.5 X ULN (however, >3.0 mg/dL is acceptable in cases of Gilbert syndrome)
    • Severe renal impairment ( \<30 mL/min/1.73 m² calculated using the MDRD formula*),

      * eGFR = 175 X (Serum creatinine)-1.154 X (Age)-0.203 X (0.742 (for females)) X (1.212 (for African Americans))

    • TSH >6.0 mIU/L or \<0.4 mIU/L,
  • Subjects with a lifetime history of suicide attempts
  • Subjects with a PHQ-9 score of 10 or higher at screening
  • Subjects who answer affirmatively to item 4 or 5 on the C-SSRS at screening
  • Pregnant or breastfeeding women
  • Females of and males who do not agree to use adequate # until at least 2 weeks after the last dose of the IP or who plan to conceive during the study period,

    • Adequate contraception is defined as double contraception using both barrier methods (male condom or female condom) and one of the contraceptive methods ①-③.

      • Hormonal contraceptive (oral, injectable, implantable, etc.), ② Implantation of Intrauterine device (IUD) or intrauterine system (IUS), ③ Sterilization procedures or surgeries (bilateral tubal ligation, hysterectomy, vasectomy), ④ Complete abstinence: absolute abstinence is accepted if, in the investigator's judgment, the subject's age, occupation, lifestyle, or sexual orientation ensure compliance with contraception. However, periodic abstinence (calendar method, ovulation method, symptothermal method, etc.) withdrawal, and coitus interruptus are not considered adequate contraceptive methods.,
  • Subjects who have participated in another clinical trial and received an drug or device within 4 weeks prior to screening
  • Other reasons (such as a medical history of alcohol or substance abuse) that the investigator deems the subject unsuitable for participation in this clinical trial
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Placebo comparator
    1 stage Control Group_Placebo

    Administer orally three tablets once daily for 12 weeks (three tablets of 60mg placebo). This group will match the investigational drug in appearance but contain no active ingredients to maintain blinding.

    Drug: Placebo

  • Experimental
    1 stage Treatment Group 1_KDS2010 120mg

    Administer orally three tablets once daily for 12 weeks (two tablets of KDS2010 60mg and one tablet of 60mg placebo). This group will receive the active investigational drug to evaluate its safety and efficacy.

    Drug: KDS2010 · Drug: Placebo

  • Placebo comparator
    2 stage Control Group_Placebo

    Administer orally three tablets once daily for 12 weeks (three tablets of 60mg placebo). This group will match the investigational drug in appearance but contain no active ingredients to maintain blinding.

    Drug: Placebo

  • Experimental
    2 stage Treatment Group 1_KDS2010 180mg

    Administer orally three tablets once daily for 12 weeks (three tablets of KDS2010 60mg). This group will receive the active investigational drug to evaluate its safety and efficacy.

    Drug: KDS2010

  • Placebo comparator
    3 stage Control Group_Placebo

    Administer orally four tablets once daily for 12 weeks (four tablets of 60mg placebo). This group will match the investigational drug in appearance but contain no active ingredients to maintain blinding.

    Drug: Placebo

  • Experimental
    3 stage Treatment Group 1_KDS2010 240mg

    Administer orally four tablets once daily for 12 weeks (four tablets of KDS2010 60mg). This group will receive the active investigational drug to evaluate its safety and efficacy.

    Drug: KDS2010

Interventions

  • DrugKDS2010

    KDS2010 will be administered orally once daily, two tablets per day, for 12 weeks. Dosage will be 120 mg depending on the assigned group.

  • DrugKDS2010

    KDS2010 will be administered orally once daily, three tablets per day, for 12 weeks. Dosage will be 180 mg depending on the assigned group

  • DrugKDS2010

    KDS2010 will be administered orally once daily, four tablets per day, for 12 weeks. Dosage will be 240mg depending on the assigned group.

  • DrugPlacebo

    Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, one tablets per day, for 12 weeks.

  • DrugPlacebo

    Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, three tablets per day, for 12 weeks.

  • DrugPlacebo

    Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, four tablets per day, for 12 weeks.

07

What researchers measure

Primary outcomes

  1. Percentage Change in Body Weight from Baseline

    The percentage change in body weight from baseline to Week 12 after administration of the investigational product (KDS2010).

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Proportion of Subjects with ≥5%, ≥10%, ≥15%, and ≥20% weight loss from baseline (%)

    Proportion (%) of subjects with ≥5%, ≥10%, ≥15%, and ≥20% weight loss at week 12 after IP administration compared to baseline

    Time frame: Baseline to Week 12

  2. Change from baseline in Waist Circumference

    Waist circumference will be measured to the nearest 0.1 cm using a tape measure while the participant stands with feet approximately 25-30 cm apart, distributes body weight evenly, and exhales comfortably. Changes will be assessed up to Week 12.

    Time frame: Screening(Week -4 to -2), Run-in(Week -2), Baseline(Week 0), Week 4, 8, 12

  3. Change from baseline in Body Mass Index (BMI)

    Change from baseline to Week 12 in BMI, calculated as weight in kilograms divided by height in meters squared (kg/m²).

    Time frame: Screening(Week -4 to -2), Run-in(Week -2), Baseline(Week 0), Week 4, 8, 12

  4. Change from baseline in Systolic and Diastolic Blood Pressure

    Change from baseline in systolic and diastolic blood pressure measured in mmHg.

    Time frame: Screening(Week -4 to -2), Run-in(Week -2), Baseline(Week 0), Week 4, 8, 12, 13

  5. Change from baseline in Impact of Weight on Quality of Life Questionnaire-Lite Clinical Trials version (IWQOL-Lite-CT) Total and Domain Scores

    Change from baseline to Week 12 in the total score and domain-specific scores of the IWQOL-Lite-CT. IWQOL-Lite-CT is a questionnaire used to assess weight-related quality of life, consisting of 20 items. Each of the 20 items is evaluated on a scale of 0 to 5 points. Higher scores indicate better quality of life.

    Time frame: Baseline(Week 0), Week 12

  6. Change from baseline in Body Fat Composition via Dual-energy X-ray absorptiometry (DEXA) Scan

    Change from baseline to Week 12 in percent body fat composition(changes in body fat mass and lean muscle mass) measured by DEXA scan.

    Time frame: Baseline(Week 0), Week 12

  7. Change from baseline in Lipid Profile

    Change from baseline in lipid parameters, including Total Cholesterol (TC), Triglycerides (TG), High-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C), Very low-density lipoprotein cholesterol (VLDL-C) and Free Fatty Acids.

    Time frame: Screening(Week -4 to -2), Baseline(Week 0), Week 4, 8, 12, 13

  8. Change from baseline in Glycemic Parameters: HbA1c (%)

    Change from baseline in Hemoglobin A1c (HbA1c) (percentage)

    Time frame: Screening(Week -4 to -2), Baseline(Week 0), Week 4, 8, 12, 13

  9. Change from baseline in Glycemic Parameters: Fasting Glucose (mg/dL)

    Change from baseline in fasting glucose levels (mg/dL).

    Time frame: Screening(Week -4 to -2), Baseline(Week 0), Week 4, 8, 12, 13

  10. Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Change from baseline to Week 12 in HOMA-IR index. HOMA-IR is calculated using fasting insulin and fasting glucose levels to predict insulin resistance.

    Time frame: Baseline(Week 0), Week 12

  11. Change from baseline in Liver Steatosis (Abdominal CT)

    Change from baseline to Week 12 in liver fat content assessed by Abdominal CT.

    Time frame: Baseline(Week 0), Week 12

Other outcomes

  1. Number of subjects with treatment-related Adverse Events (AEs)

    AEs will be coded using MedDRA and assessed for severity and causality using CTCAE v5.0. The number of subjects affected and the incidence rates will be presented for each treatment group.

    Time frame: Conducted from screening (Week -4 to -2) through Treatment (Week 0 to 12) and Follow-up (Week 13)

  2. Change from baseline in laboratory test results

    Laboratory parameters including routine hematology, blood chemistry, urinalysis, lipid, coagulation, hormone will be measured. Change from baseline will be analyzed.

    Time frame: Screening(Week -4 to -2), Baseline(Week 0), Week 4, 8, 12, 13

  3. Change from baseline in pulse rate

    Pulse rate will be measured in beats per minute.

    Time frame: Screening(Week -4 to -2), Run-in(Week -2), Baseline(Week 0), Week 4, 8, 12, 13

  4. Change from baseline in body temperature

    Body temperature will be measured using a standard thermometer.

    Time frame: Screening(Week -4 to -2), Run-in(Week -2), Baseline(Week 0), Week 4, 8, 12, 13

  5. Change from baseline in Electrocardiogram(ECG)

    For ECG results, the proportion of subjects whose status changed from 'Normal or Abnormal Not Clinically Significant (Abnormal NCS)' before the IP administration to 'Abnormal Clinically Significant (Abnormal CS)' after IP administration will be summarized and presented in a table.

    Time frame: Screening(Week -4 to -2), Week 12, 13

  6. Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) total score

    C-SSRS is used to assess the risk of suicide through interviews with the subject. The scores of each question are summed to range from 0 to 25 points. If "yes" from questions 4 or 5, categorize a subject as high-risk, requiring further evaluation, while other scores indicate a lower risk.

    Time frame: Screening(Week -4 to -2), Baseline(Week 0), Week 4, 8, 12

  7. Change from baseline in Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a validated self-report tool used to screen for and assess the severity of depressive symptoms. It consists of nine items, each rated on a 4-point scale from 0 ("not at all") to 3 ("nearly every day"), with a total possible score ranging from 0 to 27. Higher scores indicate greater severity of depressive symptoms.

    Time frame: Screening(Week -4 to -2), Baseline(Week 0), Week 4, 8, 12

  8. Proportion of Subjects with ≥25% Weight Loss at Week 12

    Proportion (%) of subjects with ≥25% weight loss at week 12 after IP administration compared to baseline.

    Time frame: Baseline to Week 12

  9. Percentage Change in Monoamine Oxidase B (MAO-B) Specific Activity

    Percentage change in MAO-B specific activity compared to baseline (%)

    Time frame: Baseline(Week 0), Week 12

  10. Percentage Change in Adiponectin Levels

    Percentage change in Adiponectin compared to baseline (%)

    Time frame: Screening(Week -4 to -2), Baseline(Week 0), Week 4, 8, 12, 13

  11. Pharmacokinetic Parameters: Area Under the Plasma Concentration-Time Curve over the dosing interval (τ) (AUCtau) at steady-state

    AUCtau is the area under the plasma concentration-time curve over the dosing interval (τ) at steady-state, and it reflects the extent of drug exposure within a dosing cycle.

    Time frame: Baseline(Week 0), Week 4, 8, 12

  12. Pharmacokinetic Parameters: Peak Plasma Concentration at Steady State (Cmax,ss)

    The highest plasma drug concentration observed during a dosing interval at steady-stat

    Time frame: Baseline(Week 0), Week 4, 8, 12

  13. Pharmacokinetic Parameters: Minimum Plasma Concentration at Steady State (Cmin,ss)

    The lowest plasma drug concentration during a dosing interval at steady-state, usually occurring right before the next dose.

    Time frame: Baseline(Week 0), Week 4, 8, 12

  14. Pharmacokinetic Parameters: Average Plasma Concentration at Steady State (Cav,ss)

    The average plasma concentration over the dosing interval at steady-state. Calculated as: Cav, ss = AUCtau/τ

    Time frame: Baseline(Week 0), Week 4, 8, 12

  15. Pharmacokinetic Parameters: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)

    The time taken to reach the maximum plasma concentration after dosing at steady-state.

    Time frame: Baseline(Week 0), Week 4, 8, 12

  16. Pharmacokinetic Parameters: Terminal Elimination Half-life (t1/2)

    The time required for the plasma concentration of the drug to decrease by half.

    Time frame: Baseline(Week 0), Week 4, 8, 12

  17. Pharmacokinetic Parameters: Peak-Trough Fluctuation at Steady State (PTF)

    A measure of the fluctuation between the peak (Cmax,ss) and trough (Cmin,ss) plasma concentrations during a dosing interval.

    Time frame: Baseline(Week 0), Week 4, 8, 12

08

Study locations

3 of 3 sites recruiting
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Gyeonggi-do 16247, South Korea
    Recruiting
    • Sangwook Song, Professor · Contactjenny.kim@mdnf.co.kr · +82)2-6959-9927
    • Hana Kim, Professor · Contact
    • Sangwook Song, Professor · Principal investigator
  • Kangbuk Samsung Medical Center
    Seoul, Seoul 03181, South Korea
    Recruiting
    • Jaeheon Kang, Professor · Contactjenny.kim@mdnf.co.kr · +82)2-6959-9927
    • Sujeong Shin, Professor · Contact
    • Jaeheon Kang, Professor · Principal investigator
  • Yonsei University Health System, Severance Hospital
    Seoul, Seoul 03722, South Korea
    Recruiting
    • Jiwon Lee, Professor · Contactjenny.kim@mdnf.co.kr · +82)2-6959-9927
    • Jia Lee, CRC · Contact
    • Jiwon Lee, Professor · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 18 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Jun 6, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07009171
Lead sponsor
NeuroBiogen Co., Ltd
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Jul 29, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Jaeheon Kang, Professor
Contact
jenny.kim@mdnf.co.kr
+82)2-6959-9927
Sujeong Shin, Professor
Contact
Sangwook Kim, Chief Executive Officer
study director · NeuroBiogen Co., Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion